LBT Innovations Ltd
ASX:LBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
LBT Innovations Ltd
Cash & Cash Equivalents
LBT Innovations Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LBT Innovations Ltd
ASX:LBT
|
Cash & Cash Equivalents
AU$2.3m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
3%
|
|
|
Somnomed Ltd
ASX:SOM
|
Cash & Cash Equivalents
AU$18m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
9%
|
|
|
Cochlear Ltd
ASX:COH
|
Cash & Cash Equivalents
AU$187.1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
9%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Cash & Cash Equivalents
AU$17.7m
|
CAGR 3-Years
79%
|
CAGR 5-Years
14%
|
CAGR 10-Years
34%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Cash & Cash Equivalents
AU$15.2m
|
CAGR 3-Years
30%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Cash & Cash Equivalents
AU$17.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
LBT Innovations Ltd
Glance View
LBT Innovations Ltd. is an Australian developer of clinical and diagnostic technology, which has emerged as a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefits for busy clinical laboratories. The company is headquartered in Adelaide, South Australia. The company went IPO on 2006-07-31. The firm is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets. The firm's product pipeline includes The Automated Plate Assessment System for antimicrobial resistance (APAS-AMR), WoundVue, Biofilm, Automated Gram Stain Assessment and MicroStreak. The firm's Automated Plate Assessment System (APAS) Independence is a platform technology that automates culture-plate screening and interpretation. APAS Independence screens, interprets, and sorts these plates, overcoming the bottleneck in lab workflows and freeing up microbiologist's time. Its APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates.
See Also
What is LBT Innovations Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.3m
AUD
Based on the financial report for Jun 30, 2024, LBT Innovations Ltd's Cash & Cash Equivalents amounts to 2.3m AUD.
What is LBT Innovations Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
3%
Over the last year, the Cash & Cash Equivalents growth was 16%. The average annual Cash & Cash Equivalents growth rates for LBT Innovations Ltd have been -38% over the past three years , -25% over the past five years , and 3% over the past ten years .
